Pricing Log in Create free account

ADMA Biologics Inc (ADMA) vs NewAmsterdam Pharma Company N.V. (NAMS)

ADMA Biologics Inc and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. ADMA Biologics Inc is the larger, with a market value of $3.0B against $2.3B — 1.3× the size. NewAmsterdam Pharma Company N.V. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 16.7×. ADMA Biologics Inc grew revenue faster over the last twelve months: 6.26% against −26.4%. ADMA Biologics Inc has the higher net margin (35.1% vs −789.9%) and the higher return on invested capital (48.0% vs −23.1%). Across the 16 metrics below, ADMA Biologics Inc leads on 12 and NewAmsterdam Pharma Company N.V. on 4.

Valuation

Metric ADMA NAMS Biotechnology median
P/E 16.70 n/m 10.26
P/S 5.68 91.08 9.18
P/B 6.73 3.75 2.05
Price to free cash flow 24.54 n/m 24.81
EV/EBITDA 13.00 n/m 0.65
EV/Sales 5.83 66.59 8.98
Earnings yield 5.99% (8.88%) (34.89%)
Free cash flow yield 4.07% (6.39%) (24.52%)

Profitability

Metric ADMA NAMS Biotechnology median
Gross margin 68.53% 100.00% 65.16%
Operating margin 46.47% (900.07%) 0.00%
Net margin 35.14% (789.94%) 0.00%
Free cash flow margin 27.06% (581.64%) 0.00%
Return on equity 41.95% (30.16%) (50.12%)
Return on assets 28.04% (27.79%) (45.60%)
Return on invested capital 48.02% (23.13%) 0.00%

Growth

Metric ADMA NAMS Biotechnology median
Revenue growth (TTM) 6.26% (26.41%) 6.26%
EPS growth (last fiscal year) (25.93%) 32.81% 29.88%
Revenue growth, 5-year CAGR 64.60% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADMA NAMS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.04 11.76 4.89
Net debt to EBITDA (0.06) 2.83 1.01

Dividend

Metric ADMA NAMS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADMA NAMS Biotechnology median
Market cap 2.96b 2.26b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack